Acute Coronary Syndrome Market Research Reports

Acute Coronary Syndrome Market Research


Acute Coronary Syndrome covers the spectrum of clinical conditions ranging from unstable angina to ... view more

RSS Sort By :
TITLE Price Buy Now More options

GlobalData has released its new PharmaPoint Drug Evaluation report, "Brilinta (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins ...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Effient (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins i...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Crestor (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins i...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Xarelto (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins i...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Angiomax (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins ...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Zontivity (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Alirocumab (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statin...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Evolocumab (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and statin...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Bococizumab (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and stati...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Anacetrapib (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and stati...

$ 3495


GlobalData has released its new PharmaPoint Drug Evaluation report, "Evacetrapib (Acute Coronary Syndrome) Forecast and Market Analysis to 2023". The current ACS market primarily comprised of antithrombotics, antihypertensives, and stati...

$ 3495


Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and w...

$ 3995


Global Markets Direct's, ?Acute Coronary Syndrome Pipeline Review, H1 2014', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.This report provides comprehensive information on the therapeutic developmen...

$ 2000

Email Us
Need Help?
Name
Email
Phone
Country
Subject
Comments

Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441
Subscription Option

Use our subscription option and keep yourself updated about the latest industry analysis reports. We have research reports for over 5000 micro markets; you can access and utilize them at economical budgets.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: